Lonza Group AG Share Price

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange 09:01:33 22/07/2024 pm IST 5-day change 1st Jan Change
513.2 CHF +1.14% Intraday chart for Lonza Group AG -0.58% +45.09%

Financials

Sales 2024 * 6.65B 7.48B 626B Sales 2025 * 7.63B 8.58B 718B Capitalization 37.07B 41.69B 3,486B
Net income 2024 * 873M 982M 82.11B Net income 2025 * 1.1B 1.23B 103B EV / Sales 2024 * 5.98 x
Net Debt 2024 * 2.73B 3.08B 257B Net Debt 2025 * 3.27B 3.67B 307B EV / Sales 2025 * 5.28 x
P/E ratio 2024 *
42.8 x
P/E ratio 2025 *
34 x
Employees 18,000
Yield 2024 *
0.88%
Yield 2025 *
1.02%
Free-Float 96.69%
More Fundamentals * Estimated data
Dynamic Chart
1 day+1.14%
1 week-0.58%
Current month+4.65%
1 month+7.54%
3 months+1.26%
6 months+37.62%
Current year+45.09%
More quotes
1 week
501.40
Extreme 501.4
528.80
1 month
473.60
Extreme 473.6
528.80
Current year
339.00
Extreme 339
559.40
1 year
308.60
Extreme 308.6
559.40
3 years
308.60
Extreme 308.6
785.40
5 years
301.00
Extreme 301
785.40
10 years
90.90
Extreme 90.9
785.40
More quotes
Managers TitleAgeSince
Director of Finance/CFO 52 01/21/01
Chief Operating Officer 55 01/22/01
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 64 16/14/16
Director/Board Member 66 16/14/16
Director/Board Member 58 05/22/05
More insiders
Date Price Change Volume
22/24/22 513.2 +1.14% 164,580
19/24/19 507.4 -1.97% 155,770
18/24/18 517.6 +1.65% 194,185
17/24/17 509.2 -0.97% 147,581
16/24/16 514.2 -0.39% 134,304

Delayed Quote Swiss Exchange, July 22, 2024 at 09:01 pm IST

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (55.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (17.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.4%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (10.4%); - other (3.5%). Net sales are distributed geographically as follows: Switzerland (17.4%), Europe (31.7%), the United States (31.8%), the Americas (3.2%), Japan (8.1%), Asia (7.5%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
513.2 CHF
Average target price
586 CHF
Spread / Average Target
+14.19%
Consensus